ReviewAgeing research reviews2014
Ageing and Parkinson's disease: why is advancing age the biggest risk factor?
Review in Ageing research reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 457 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
457 citing papers in PubMed, 3 syntheses or guidelines pooled it, 938 citations in OpenAlex.
- Effects of exercise on α-synuclein in rodent models of Parkinson's disease: a systematic review and meta-analysis.Experimental brain research · 2026Pooled it
- Global trends of early-onset Parkinson's disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.Frontiers in neurology · 2025Pooled it
- MicroRNAs in Parkinson's disease: a systematic review and diagnostic accuracy meta-analysis.Scientific reports · 2023Pooled it
- Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson's disease clinical trial.Stem cell research & therapy · 2025Trial
- Migraine and Risk of Parkinson Disease in Women: A Cohort Study.Neurology · 2024Trial
- Multi-Network Co-expression Analysis Enhances Biological Insights from Single-Cell Gene Expression.Interdisciplinary sciences, computational life sciences · 2026Article
- The safety and tolerability of opicapone in elderly Parkinson's disease patients: a real-world, multicenter, retrospective study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- TLR2 Regulates α-Synuclein Phosphorylation and Release in an Enteroendocrine Cell Model.Molecular neurobiology · 2026Article
- Perspectives on ionizing radiation and Parkinson's disease.NPJ Parkinson's disease · 2026Review
- Deterministic selection and compositional turnover in Parkinson's disease-associated gut dysbiosis.Antonie van Leeuwenhoek · 2026Article
- BAGE: a Bayesian framework for age prediction based on PBMC gene expression data.BMC bioinformatics · 2026Article
- Low-intensity transcranial ultrasound neuromodulation promotes neuronal regeneration: A new hope for noninvasive treatment of neurodegenerative diseases.Neural regeneration research · 2026Article
- The Extract ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Validation of remote multimodal AI screening for Parkinson disease across diverse settings.Communications medicine · 2026Article
- Association of Sarcopenia With Cognitive Function in Patients With Parkinson's Disease: A Cross-Sectional Study.Brain and behavior · 2026Article
- Article
- Foslevodopa-Foscarbidopa subcutaneous infusion in Parkinson's disease: a cross-cultural/cross-racial international multicentre comparative tolerability study (CRIM-FOS study).Scientific reports · 2026Article
- Single-nucleus multiomic profiling of the aging mouse substantia nigra reveals conserved gene alterations linked to Parkinson's disease.Genome research · 2026Article
- Task-specific dynamical entropy variations in EEG as a biomarker for Parkinson's disease progression.GeroScience · 2026Article
- Protocol for combining BMP, MEK, WNT inhibition and iNGN2 to enable rapid neuronal differentiation and regional patterning from hiPSCs.STAR protocols · 2026Article
397 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
As the second most common age related neurodegenerative disease after Alzheimer's disease, the health, social and economic impact resulting from Parkinson's disease will continue to increase alongside the longevity of the population. Ageing remains the biggest risk factor for developing idiopathic Parkinson's disease. Although research into the mechanisms leading to cell death in Parkinson's disease has shed light on many aspects of the pathogenesis of this disorder, we still cannot answer the fundamental question, what specific age related factors predispose some individuals to develop this common neurodegenerative disease. In this review we focus specifically on the neuronal population associated with the motor symptoms of Parkinson's disease, the dopaminergic neurons of the substantia nigra, and try to understand how ageing puts these neurons at risk to the extent that a slight change in protein metabolism or mitochondrial function can push the cells over the edge leading to catastrophic cell death and many of the symptoms seen in Parkinson's disease. We review the evidence that ageing is important for the development of Parkinson's disease and how age related decline leads to the loss of neurons within this disease, before describing exactly how advancing age may lead to substantia nigra neuronal loss and Parkinson's disease in some individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.